Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its financial results for the 17 months ended 31 December 2019 on Tuesday, 21 April 2020.
An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 21 April 2020 at finnCap’s offices, 60 New Broad St, London EC2M 1JJ.
Avacta Group is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.